Assessing the long-term effects of microbial therapeutics as treatment within psychiatry

A systematic review

Bibliographic Data

ID15522382
AuthorsCassandra Sgarbossa (0000-0001-5779-1067, Providence Health Care, corresponding author), Arthi Chinna Meyyappan (0000-0003-3424-4196, Providence Health Care), Evan Forth (0000-0002-4284-0249, Providence Health Care), Hayley Bromley (Providence Health Care), Roumen Milev (0000-0001-6884-171X, Providence Health Care)
Year2026
Volume16
Pages1663719-1663719
Publication date2026-01-12
Open AccessYes
TypeARTICLE
VenueFrontiers in Psychiatry (JOURNAL)
Journal identifiersISSN: 1664-0640 • E-ISSN: 1664-0640
PublisherFrontiers Media (PUBLISHER • CH)
DOI10.3389/fpsyt.2025.1663719
PMID41601518
OpenAlexW7122426614
LanguageEN
References cited51

Overall, this review highlighted the need for more placebo-controlled studies with larger sample sizes to effectively evaluate the longitudinal potential of microbial therapeutics as treatment for mood-disturbances and psychiatric symptoms. With consideration for the limitations of this field, these results provide evidence that there may be long-term benefits of targeting the gut microbiome as treatment for mood-related disturbances

Clinical trial · Gut microbiome · Human microbiome · MEDLINE · Metagenomics · Microbiome · Gut microbiota and health · Treatment of Major Depression · Tryptophan and brain disorders

Tools

Open DOIOpen Access